Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).
Bewersdorf JP, Xie Z, Bejar R, Borate U, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, Porta MGD, DeZern AE, Fenaux P, Figueroa ME, Gore SD, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim TK, Komrokji R, Kuchroo VK, List AF, Loghavi S, Majeti R, Odenike O, Patnaik MM, Platzbecker U, Roboz GJ, Sallman DA, Santini V, Sanz G, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Xu ML, Savona MR, Wei AH, Zeidan AM. Bewersdorf JP, et al. Among authors: loghavi s. Blood Rev. 2023 Jul;60:101072. doi: 10.1016/j.blre.2023.101072. Epub 2023 Mar 11. Blood Rev. 2023. PMID: 36934059 Review.
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.
Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Bose P, et al. Among authors: loghavi s. Blood. 2018 Nov 8;132(19):2100-2103. doi: 10.1182/blood-2018-05-848473. Epub 2018 Sep 21. Blood. 2018. PMID: 30242087 Free PMC article. No abstract available.
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM, Glytsou C, Fleming SA, Zhang Q, Ma H, Patel KP, Kornblau SM, Xu Z, Chua CC, Chen X, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang DCS, Roberts AW, Majewski IJ, Konopleva M, Wei AH. DiNardo CD, et al. Among authors: loghavi s. Blood. 2020 Mar 12;135(11):791-803. doi: 10.1182/blood.2019003988. Blood. 2020. PMID: 31932844 Free PMC article.
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.
Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Lachowiez CA, et al. Among authors: loghavi s. Blood Adv. 2020 Apr 14;4(7):1311-1320. doi: 10.1182/bloodadvances.2019001267. Blood Adv. 2020. PMID: 32251497 Free PMC article.
SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival.
Wudhikarn K, Loghavi S, Mangaonkar AA, Al-Kali A, Binder M, Carr R, Reichard K, Finke C, Howard M, Gangat N, Tefferi A, Komrokji R, Ali N, Lasho T, Ketterling R, Padron E, Patnaik MM. Wudhikarn K, et al. Among authors: loghavi s. Blood Adv. 2020 Nov 24;4(22):5716-5721. doi: 10.1182/bloodadvances.2020003345. Blood Adv. 2020. PMID: 33216886 Free PMC article. No abstract available.
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.
Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Maiti A, et al. Among authors: loghavi s. Blood Cancer J. 2021 Feb 1;11(2):25. doi: 10.1038/s41408-021-00410-w. Blood Cancer J. 2021. PMID: 33563904 Free PMC article. Clinical Trial. No abstract available.
Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.
Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Venugopal S, et al. Among authors: loghavi s. Am J Hematol. 2021 May 1;96(5):E154-E157. doi: 10.1002/ajh.26122. Epub 2021 Feb 19. Am J Hematol. 2021. PMID: 33580980 Free PMC article. Clinical Trial. No abstract available.
Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study.
Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver N, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Reville PK, et al. Among authors: loghavi s. Blood Cancer J. 2021 Mar 17;11(3):60. doi: 10.1038/s41408-021-00453-z. Blood Cancer J. 2021. PMID: 33731681 Free PMC article. Clinical Trial. No abstract available.
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.
Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Lachowiez CA, et al. Among authors: loghavi s. Blood Adv. 2021 Apr 27;5(8):2173-2183. doi: 10.1182/bloodadvances.2020004173. Blood Adv. 2021. PMID: 33885753 Free PMC article.
233 results